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Bronchoalveolar lavage (BAL) cells and peripheral blood leucocytes (PBL) from 24 lung transplant recipients 
were analysed for leucocyte subsets and expression of cell surface antigens. Total and differential white cell 
counts were performed on BAL, and lymphocyte subsets were evaluated in both BAL and peripheral blood. 
Measurement of immunofluorescence by flow cytometry was used to assess the percentage of: T cells (CD3 +); 
T-helper cells (CD4+); T-cytotoxic/suppressor cells (CD8+); and activated lymphocytes (HLA - DR+). 
Lymphocyte subsets in BAL demonstrated marked differences to those in blood. A lower percentage of CD3+ 
and CD4+ lymphocytes were found in BAL, whereas CD8+ cells were more prevalent in BAL than in PBL. 
The mean CD4:CD8 ratio was significantly lower in BAL (1:l) than in blood (2.1:1). In the absence of 
pulmonary infection, there was a trend for a lower CD4:CD8 ratio in BAL associated with acute rejection 
(1.1: 1) and obliterative bronchiolitis (1: l), when compared to the group with no evidence of rejection (1.4: 1). 
In the absence of pulmonary rejection, pulmonary infection was associated with a marginally lower CD4:CD8 
ratio in BAL (0.7:1), than when infection was absent (1.4:1). This difference was more evident in cases of 
cytomegalovirus (CMV) infection with a mean CD4:CD8 ratio of 0.3:1, compared to 1.5:1 in the absence 
of CMV disease (WO.05). 
Introduction 
Methods to monitor rejection of the pulmonary 
allograft have evolved in parallel with the clinical 
application of heart-lung transplantation (HLT) (1) 
single lung transplantation (SLT) (2) and double lung 
transplantation (DLT) (3). Transbronchial biopsy 
(TBB) is generally accepted as the most accurate 
technique for assessing both allograft rejection and 
opportunistic pulmonary infection (4). The recent 
standardization of histological grading of lung rejec- 
tion has aided in the management of these patients 
(5). However, TBB is an invasive procedure with an 
associated morbidity. 
Bronchoalveolar lavage (BAL), a relatively non- 
hazardous procedure, provides a high yield of cells 
present in the lungs, and is often used as an adjunct 
to TBB for diagnosing pulmonary infection in this 
group (6). Although BAL generally remains less 
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specific than TBB in diagnosing rejection (7) sophis- 
ticated techniques including immunohistochemistry 
(8) and biological assays such as the primed lympho- 
cyte reaction (9) have been developed to define 
further the immunological processes involved in 
rejection of the pulmonary allograft. However, these 
methods are protracted and hence not ideal for 
clinical practice. 
The fluorescence activated cell sorter (FACS) (10) 
allows the rapid analysis of diverse cell populations 
for expression of many different cell surface antigens, 
and thus may provide BAL with greater clinical 
application. FACS analysis, or flow cytometry, has 
been used for studying BAL fluid in experimental 
lung transplantation (1 l), and in other pulmonary 
diseases including fibrosing alveolitis (12) and sar- 
coidosis (13) in which all the cellular components 
of BAL were evaluated, including alveolar macro- 
phages. Although lymphocytes comprise a small 
percentage of the total cells in BAL from normal 
subjects (14), attention has been focused on this cell 
population in lung transplant recipients, as they are 
primarily implicated in mediating allograft rejection 
(15). Of particular interest in clinical transplantation 
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are T cells (CD3+), T-helper cells (CD4+), 
T-cytotoxic/suppressor cells (CD8 +), and activated T 
cells (HLA - DR+) (16). In this study we have 
analysed lymphocyte subsets in BAL fluid and 
peripheral blood from human lung transplant recipi- 
ents and correlated these with clinical, histological 
and microbiological data. 
Materials and Methods 
PATIENTS 
Bronchoalveolar lavage (BAL) was performed on 
43 occasions in 15 HLT, seven SLT and two DLT 
recipients, at the same time as transbronchial biopsy 
(TBB). The latter was performed for either acute 
clinical deterioration associated with a fall in pulmo- 
nary function, or as routine surveillance for graft 
rejection, as described previously (17). 
Patients ranged from 13-53 years (mean, 36.2 
years), with 11 males and 13 females. All received 
maintenance triple immunosuppression therapy 
consisting of oral cyclosporin A (CyA), adminis- 
tered (mean dose, 9.3 mg kg ~ ’ day- ‘) to maintain 
plasma levels at 150-300 ng ml ~ ’ (radioimmuno- 
assay method) azathioprine (mean dose, 
1.7 mg kg - ’ day ‘) and prednisone (mean dose, 
0,4mgkgg’day-‘). In addition, an anti- 
lymphocyte preparation (rabbit anti-thymocyte 
globulin - supplied by C. Bieber, Specific Antisera, 
Fremont, CA, U.S.A. [n=12]; or OKT3 -0rtho 
Pharmaceuticals, Raritan, NJ, U.S.A. [n= 121) was 
given in the early post-operative period as prophy- 
laxis for graft rejection. High dose intravenous 
methylprednisolone (1 g day ’ x 3), followed by a 
reducing oral prednisone course (commencing at 
1 mg kg ~ ’ day - ‘) was administered for episodes 
of acute rejection. Post-transplant survival of the 
cohort ranged from 0.5-100.5 months (mean, 13.4 
months). 
BRONCHOALVEOLAR LAVAGE (BAL) 
Fibre optic bronchoscopy, BAL and TBB were 
performed on patients after sedation and application 
of topical anaesthesia to the upper airways. The 
flexible fibre optic bronchoscope (Olympus, Tokyo, 
Japan) was wedged into a subsegmental bronchus of 
either the right middle or left lingular lobe, and 
warmed, pH-corrected normal saline (0.275 ml of 
8.4% sodium bicarbonate in 500 ml of normal saline) 
was instilled in 3 x 60 ml aliquots. BAL fluid was 
aspirated into a siliconized glass container, using 
gentle suction (200-300 mmHg) avoiding trauma to 
the bronchial mucosa. A sample of BAL fluid (15 ml) 
was removed for microbiological and cytological 
examination. After BAL, TBB was performed from 
both lower lobes. 
BAL fluid was initially filtered through four layers 
of surgical cotton gauze, the cells pelleted by centrifu- 
gation at 320 RCF for 5 min, washed twice in the cell 
medium RPMI-1640 (Irvine Scientific Products, 
Santa Ana, CA, U.S.A.), and re-suspended in 10 ml 
of RPMI-1640. Total and differential white blood cell 
counts were performed, the former on a Coulter 
counter (Coulter, Hialeah, FL, U.S.A.), the latter 
manually on a Wright-Giemsa stained cytocentrifuge 
preparation. 
A volume of the resulting suspension, containing 
at least 1.5 x 10’ white cells, was diluted in 10 ml of 
phosphate buffered saline (PBS), and layered on top 
of 4 ml of ficoll-hypaque lymphocyte separation 
medium (LSM - Organon Teknika, Durham, NC, 
U.S.A.). This was centrifuged at 750 RCF for 30 min 
to separate mononuclear cells, as previously 
described (18). The cell layer was removed, washed in 
10 ml PBS on three occasions (centrifuged at 750, 150 
and 320 RCF, respectively for 10 min each) and 
suspended in 1 ml of PBS. 
MONOCLONAL ANTIBODY (MAB) STAINING OF BAL AND 
PERIPHERAL BLOOD LYMPHOCYTES 
One hundredpl (approx 1 x lo6 cells) of the above 
prepared BAL cells were aliquoted into individual 
test tubes for each mAb. In addition, 100~1 of 
heparinized whole blood (approx 0.7 x lo6 white 
cells), collected at the time of bronchoscopy, was 
aliquoted into a duplicate set of tubes, and washed 
twice in PBS. The mAb panel, and the amounts of 
each used, were as follows: OKT3 (0.3 pug) and OKT4 
(0.3 pg - Ortho Diagnostic Systems, Raritan, NJ, 
U.S.A.) for CD3 and CD4, respectively; RPATS 
(0.3pg - supplied by Dr G Averson, DNAX 
Research Institute, Palo Alto, CA, U.S.A.) for CD8; 
and L243 (1 pug - American Type Culture Collection, 
Rockville, MD, U.S.A.) a pan MHC class 11 
(HLA - DR) marker. 
All antibodies were conjugated with fluoroscein 
isothiocynate (FITC), except L243, which required a 
second step stain with FITC-conjugated goat anti- 
mouse antibody (1.25 pug - TAGO, Burlingame, CA, 
U.S.A.). The mAb was incubated with cells for 
15 min at room temperature, and washed in PBS 
prior to the second step antibody when required. 
After two further washes in PBS, BAL cells were 
fixed in 0.5% paraformaldehyde. The peripheral 
blood samples were firstly treated with whole blood 
lysis (Coulter, Hialeah, FL, U.S.A.) to remove 
erythrocytes, and washed twice in PBS before fixing 
in 0.5% paraformaldehyde. 
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FLOW CYTOMETRY 
Immunofluorescence of the stained BAL and 
peripheral blood lymphocytes was measured on a 
FACScan (Becton Dickinson, Mountain View, CA, 
U.S.A.). Subsequent generation of graphics and 
analysis of the lymphocyte subsets were performed 
on a VAX computer using software (‘Electric desk’) 
developed by the shared FACS facility at Stanford 
University School of Medicine. This was locally 
accessed and displayed on a Macintosh 11x personal 
computer (Apple Computer, Cupertino, CA, 
U.S.A.). Results of the analyses (i.e. CD3+, CD4+, 
CDS +, and HLA - DR +) were described as percent- 
ages of total lymphocytes. To assist in comparison 
between the different diagnostic categories, 
CD4:CD8 ratios were calculated. 
DIAGNOSIS OF PULMONARY REJECTION AND INFECTION 
Pulmonary allograft rejection was categorized into 
three groups; nil rejection (NR), acute rejection (AR) 
and obliterative bronchiolitis (OB). A diagnosis of 
acute rejection was made in the presence of histologi- 
cal changes on TBB, i.e. grades 14 of the Interna- 
tional Society of Heart and Lung Transplantation 
(ISHLT) nomenclature (5), and/or when chest X-ray 
infiltrates cleared, or an acute fall in pulmonary 
function tests reversed, on augmented immunosup- 
pression therapy (e.g. intravenous steroids or anti- 
lymphocyte preparation). Obliterative bronchiolitis 
was diagnosed histologically, i.e. category C of the 
ISHLT nomenclature (5) and/or when irreversible 
chronic lung obstruction on pulmonary function 
monitoring was evident (a forced expiratory flow at 
25-75% of vital capacity [FEF,,_,,] less than 30% of 
predicted normal for more than 2 months) (19). 
Patients with OB remained in this category unless 
intervening acute rejection was diagnosed. 
Pulmonary infection (INF) was diagnosed in the 
presence of clinical symptoms (viz cough, ausculatory 
changes and pulmonary infiltrates on chest X-ray), a 
positive BAL culture, and improvement after appro- 
priate antimicrobial therapy. Infectious agents were 
classified into pathogenic bacterial, viral or other. A 
diagnosis of CMV pneumonitis (infection) required 
the presence of a clinical syndrome, histological 
identification of viral inclusions, together with 
isolation of CMV from either BAL or TBB. CMV 
colonization indicated isolation of the virus, but 
without the clinical or histological criteria. 
STATISTICAL ANALYSIS 
Data were analysed using Statview II software 
(Abacus Concepts, Berkeley, CA, U.S.A.) on a 
Macintosh 11x personal computer. Comparison of 
BAL and peripheral blood results, and analysis of 
infection data, were made using Student’s t-test. 
Comparison of results in the different rejection cat- 
egories (viz NR, AR, and OB) was made by analysis 
of variance, with probability calculated by the F and 
Fisher PLSD tests. A P value of less than 0.05 was 
considered significant. Pulmonary rejection data 
analysis was determined in the absence of pulmonary 
infection and, conversely, pulmonary infection data 
were analysed after excluding pulmonary rejection. 
As the clinical diagnosis in individual patients varied 
at different points, repeated BAL procedures in the 
same patient were considered as separate events. 
Results 
A total of 43 BAL and 38 peripheral blood samples 
were collected from 24 lung transplant recipients. 
BAL volume return averaged 59.3% of input, 
with the total white blood cell count ranging from 
0.1-33 X lo5 ml ~ ’ (mean, 3.3 X 10’ ml ~ ‘). 
FLOW CYTOMETRY 
BAL cells and PBL were analysed by flow cytom- 
etry in parallel. Lymphocyte populations were easily 
distinguishable in peripheral blood samples by their 
characteristic size (forward scatter) and granularity 
(orthogonal scatter) on the FACS probability graph 
[Fig. l(a)]. Although this population was less clearly 
isolated in BAL samples, a definite lymphocyte popu- 
lation could also be observed and their percentage 
calculated [Fig. l(b)]. After gating the lymphocytes, 
fluorescence for each mAb, and the relative number 
of positively stained cells were determined. Accord- 
ingly, the percentage of the various phenotypes in 
BAL and peripheral blood could be evaluated 
[Fig. l(c) and l(d)]. 
BAL VERSUS PERIPHERAL BLOOD 
Significant differences (non-paired results) were 
noted in the distribution of lymphocyte subsets in 
BAL when compared to peripheral blood (Fig. 2). 
The percentage (mean + SD) of: CD3+ lymphocytes 
was 63.6 & 19.4% in BAL, compared to 75.8 f 10.9% 
in blood (P=O.OOl); CD4+ lymphocytes was 
26.5 * 15.6% in BAL compared to 38.0 f 20.9% in 
blood (P=O.O06); CD8+ lymphocytes was 
37.9 f 18.3% in BAL compared to 27.9 * 11.8% in 
blood (P=O.OOS). The calculated mean CD4:CD8 
ratio in BAL was l:l, compared to 2.1:1 in blood 
(P=O.O08). These differences remained when paired 
results, i.e. BAL and peripheral blood from the same 
patient, were analysed (data not shown). However, 
there was no difference (P=O.6) observed in the 
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Fig. I Flow cytometric plots showing characteristic size (forward scatter) and granularity (orthogonal scatter) of 
lymphocytes in (a) peripheral blood and (b) BAL. After gating the lymphocyte population (as indicated by boxes), the 
relative number of cells bound to monoclonal antibodies (positive fluorescence) was assessed. Examples of CD3+ 
lymphocytes in (c) peripheral blood and (d) BAL are shown, from a patient with acute rejection. 
percentage of HLA - DR+lymphocytes in BAL (NR), six were associated with histologically proven 
(15.5 f 11.8%) compared to blood (16.8 f 12.5%). acute rejection (AR: two with grade 1; three with 
grade 2; and one with grade 4 acute rejection), and 
PULMONARY REJECTION four with obliterative bronchiolitis (OB). Although 
The diagnosis of pulmonary rejection and infection there were no differences in the total BAL cell count 
in the lung transplant recipients relating to the 43 between the groups, there was a decreased percentage 
BAL samples are shown in Table 1. After excluding of macrophages, with an associated increase 
those samples with infection, 14 showed no rejection (PcO.05) in granulocytes in the AR group (Table 2). 
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CD3+ CD4+ CD8+ HLA-DR+ 
Fig. 2 CD3+, CD4+, CD8+ and HLA - DR+ lympho- 
cytes present in BAL and peripheral blood. Data are 
expressed as mean (SD) percentage of total lymphocytes. 
*P<O.O5 by Student’s r-test. n BAL; t?Z Blood. 
There was also a higher mean percentage of lympho- 
cytes in the AR and OB groups, but this did not 
reach statistical significance (Table 2). 
The mean percentage of CD3+ lymphocytes in 
BAL remained relatively unchanged when comparing 
the three rejection categories (NR, 57.0%; AR, 
61 .O%; OB, 60.0%), as it did in peripheral blood (NR, 
72.8%; AR, 785%; OB, 80.0%). The mean percentage 
of HLA - DR+ (i.e. activated) lymphocytes in BAL 
showed no significant differences when analysed 
for rejection (NR, 16.3%; AR, 15.0%; OB, 26.6%) 
although there was a trend for an increased percent- 
age in the OB group. Analysis of PBL also failed to 
show any correlation (NR, 20.0%; AR, 22.3%; OB, 
19.1%). 
The mean CD4:CD8 ratio in BAL was lower in 
bothAR(l~l:l)andOB(l:l),whencomparedtoNR 
(1.4: l), whilst in peripheral blood, the mean 
Table 1 Pulmonary rejection and pulmonary infection in 
lung transplant recipients 
Rejection* 
No. INFt 
n (%;I)$ 
INF 
n (‘%I) 
Total 
n (7%) 
NR 14 (32.5) 14 (32.5) 28 (65) 
AR 6 (14) 3 (7) 9 (21) 
OB 4 (9) 2 (5) 6 (14) 
Total 24 (55.5) 19 (44.5) 43 (100) 
*NR, nil rejection; AR, acute rejection; OB, obliterative 
bronchiolitis. 
tINF, pulmonary infection. 
$Number of patients and percentage of total. 
CD4:CD8 ratio was marginally elevated in AR (2: l), 
and lower in OB (1.4:1), when compared to NR 
(1.7:1). However, these differences failed to reach 
statistical significance (Fig. 3). 
PULMONARY INFECTION 
After excluding cases with pulmonary rejection, 
pulmonary infection (INF) was diagnosed on 14 
occasions. Pathogenic bacteria were isolated in 11 
cases, viruses in five, and others in two (namely 
Pneumocystis carinii and Legionella pneumophila). 
Multiple organisms were noted in three cases. The 
mean white cell count in BAL was marginally higher 
when infection was present, with the percentage of 
macrophages significantly lower. Understandably, 
this was due to a relative increase in the percentage of 
granulocytes (Table 2). 
The mean ( f SD) percentage of CD3+ lympho- 
cytes in BAL associated with INF was 67.9 & 19.6%, 
compared to 57.0 * 24.0% when pulmonary infection 
was not present (P=O.O2). This trend was not 
detected in peripheral blood, where the percentage of 
Table 2 Total and differential white cell count in bronchoalveolar lavage from lung transplant 
recipients 
Diagnosis* 
(number) 
WBCt 
x IOml--’ 
Macrophage 
(‘X,) 
Granulocyte 
(‘Xl) 
Lymphocyte 
(X) 
NR/No INF (n = 14) 2.89 * 2.48 86.7 i 7.8 4.0 f 2.0 8.9 f 6.5 
AR (n=6) 1.56 f 1.48 61.8 f 22.23 7.8 zt 4.715 25.7 f 22.5 
OB (n=4) 0.72 f 0.73 74.0 =k 25.4 3.3 i I.0 22.8 f 24.8 
INF (n = 14) 4.82 f 8.43 62.8 f 30,971 16.1 f 24.9 16.2 f 17.8 
*NR, nil rejection; AR, acute rejection; OB, obliterative bronchiolitis; INF, pulmonary 
infection. 
tResults are shown as mean i SD. 
$.P<O.O5 for AR compared to NR by analysis of variance. 
$P<O.O5 for AR compared to OB by analysis of variance. 
qP<O,O5 compared to No INF by Student’s t-test. 
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Fig. 3 Mean (SD) CD4:CD8 ratios in BAL and peripheral 
blood, by rejection grade. (W NR, nil rejection; q AR, 
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Fig. 4 Sequential CD4:CDS ratios in BAL from a DLT 
(Pt 1) and an HLT (Pt 2) recipient over the first 6 months 
post-transplant. Pt 1 suffered persistent pulmonary allograft 
rejection and infection, and was associated with a reduced 
CD4:CD8 ratio. Pt 2 remained relatively free of these 
complications and maintained a relatively normal 
CD4:CD8 ratio. 0, Pt 1; n , Pt 2. 
CD3 + lymphocytes was 77.6 f 9.6% when associated 
with INF, and 72.8 k 13.8% without. 
Interestingly, there was a higher, although not 
significant, percentage of HLA - DR+ lymphocytes 
in BAL when infection was absent (16.3 + 10.20/o), 
compared to when present (13.3 k 12.3%), and this 
trend was also noted in peripheral blood with 
20.0 f 14.0% HLA - DR+ lymphocytes observed in 
the absence of infection, compared to the lower 
9.7 & 2.3% found with infection (P=O.O3). The 
CD4:CDS ratio in BAL demonstrated a marginally 
lower ratio (mean, 0.7: 1) in the presence of INF than 
in its absence (mean, 1.4:1, P=O.14), although this 
was not the case in peripheral blood (Fig. 3). 
CMV PULMONARY DISEASE 
Further analysis by patient’s CMV status was 
performed. After excluding for pulmonary rejection, 
CMV status was detailed as: infected (n=4); colo- 
nized (n=S); and nil (not colonized or infected, 
n= 16). There was an elevated total BAL cell count 
(mean 5 SD) in the infected group (10.39 f 1508) 
compared to the nil group (2.49 f 2.47), and colo- 
nized (3.30 =k 2.74), although this just failed to reach 
significance (P=O.O6). 
The mean CD4:CDS ratio in BAL was 1.51 in the 
nil group compared to 0.6:1 in the colonized group 
(P<O.O5), and 0.3:1 in the infected group (P<O.OS), 
indicating a relatively higher percentage of CD8+ 
(T-cytotoxickuppressor) lymphocytes in the presence 
of CMV colonization and infection. A similar trend 
was also observed in peripheral blood (data not 
shown). 
SEQUENTIAL STUDIES IN INDIVIDUAL PATIENTS 
The CD4:CD8 ratio in sequential BAL samples 
from an HLT and a DLT recipient over the first 6 
months post-transplant are depicted in Fig. 4. These 
patients pursued very different clinical courses. The 
HLT recipient (Pt 2), apart from early mild acute 
allograft rejection, remained free from serious pul- 
monary rejection and infection. The CD4:CD8 ratio 
in this case remained stable at a relatively normal 
value (c. 1.6:1). 
The DLT recipient (Pt 1) suffered more persistent 
allograft rejection and had numerous pulmonary 
infective episodes. The CD4:CD8 ratio in BAL in this 
case was consistently depressed at 0.2-0.3:1. This 
patient has subsequently developed OB. 
Discussion 
This preliminary study has identified flow cytom- 
etry as a useful technique in the rapid analysis of 
lymphocytes isolated by BAL from lung transplant 
recipients, and supplements the repertoire of diagnos- 
tic methods available for this patient group (20). For 
this study, numerous methods of processing BAL 
fluid were evaluated to permit satisfactory flow 
cytometry, and although other techniques have 
been advocated (21), we found the ficoll-hypaque 
separation method (11,18) the most simple and 
efficient. This method may be more appropriate when 
processing the more turbid, cellular BAL fluid, result- 
ing from the associated pulmonary rejection and 
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infection that is often present in lung transplant 
recipients. In addition, we found no differences in the 
cell distribution obtained using the ficoll-hypaque 
separation technique when compared to the whole 
blood lysis method in peripheral blood. 
A limiting factor to the use of flow cytometry to 
analyse BAL lymphocytes was the percentage of 
lymphocytes present in the sample. A minimum of 
3-5% was required to enable a definite lymphocyte 
population to be determined, gated and analysed on 
the FACS plot. Following anti-thymocyte globulin 
or OKT3 therapy, lymphocyte populations were 
detectable within the first month post-transplant. In 
addition, flow cytometric analysis should be easily 
applicable to the investigation of the other cellular 
components present in BAL, especially as their role 
in the lung allograft becomes further delineated (22). 
For these initial studies, we elected to use one 
colour immunofluorescence staining to analyse 
lymphocyte subsets in BAL and peripheral blood. 
The percentages of CD3 +, CD4+ and CD8 + 
lymphocytes in BAL, and the resultant CD4:CD8 
ratio, were significantly different to those found in 
peripheral blood. Although the mean CD4:CD8 ratio 
of 2.1:1 in blood was not remarkable, there was a 
reduced BAL ratio of 1: 1. This varied to a mean ratio 
of 1.86:1 observed in BAL fluid from a normal 
population (23). These data, indicating an elevated 
CD8+ (T-cytotoxic) lymphocyte representation in 
the lung allograft, correlate with other reports of 
this phenomenon, particularly in association with 
rejection (8,24,25). 
The high incidence (445%) of pulmonary infection 
observed in our patient group, and also seen in 
another series (26), confounds the attempts of using 
BAL as a method for diagnosing rejection. We have 
shown that flow cytometric methods applied to BAL 
may aid in the differentiation between the absence or 
presence of pulmonary infection, particularly in the 
case of CMV pneumonitis. However, to assess more 
accurately the power of this technique in diagnosing 
pulmonary rejection, a greater number of patients are 
required to allow further classification of the diag- 
nostic categories, i.e. by rejection f infection, rather 
than separately as in this study. 
By its exposure to the environment, the pulmonary 
allograft will continue to be at risk of infection and 
recently much interest has centred on CMV disease. 
Even though CMV pneumonitis is now treatable 
following the introduction of specific therapy (27,28), 
reports have shown a worse outcome for lung trans- 
plant recipients who have been infected with CMV 
(29,30). This may be related to an increased risk of 
developing chronic rejection in the presence of CMV 
disease as suggested in a recent study (31). Our data, 
demonstrating an elevated percentage of CD8+ 
(T-cytotoxic) lymphocytes in the lung allograft 
associated with both CMV colonization and 
infection, support this theory. 
The decreased percentage of HLA - DR+ (acti- 
vated) lymphocytes in both BAL and peripheral 
blood in patients with pulmonary infection was 
somewhat surprising. This may be explained by an 
increased number of immature, non-activated 
lymphocytes, recruited to deal with the infecting 
organism, or by activated cells being sequestered at 
the site of infection. 
As the cellular components of BAL vary markedly 
between normal subjects (14), more useful diagnostic 
information may be obtained by sequential studies in 
individual subjects. In the two cases illustrated, we 
have demonstrated that different clinical courses may 
be associated with variable CD4:CD8 ratios over 
time. A persistently low CD4:CD8 ratio may be 
suggestive of a worse prognostic category. Certainly, 
sequential BAL studies such as these may be more 
helpful in the clinical setting than isolated studies. 
In conclusion, flow cytometric analysis of BAL 
fluid may be safely employed in the management of 
lung transplant patients, improving the speed and 
efficiency of BAL processing. With a focus on bron- 
choalveolar lymphocytes only, we have shown data 
which may assist in the diagnosis of pulmonary 
rejection and pulmonary infection. The diagnostic 
yield may be enhanced by applying additional BAL 
data such as the relative distribution of macrophages 
and granulocytes. As the role of other cellular com- 
ponents within the alveolar space in the pulmonary 
allograft is appreciated, this technique may be more 
widely applied to enable a greater understanding of 
the immunological processes involved in rejection of 
the transplanted lung. 
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